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As a likely consequence of its capacity to
interfere with biochemical events present in
cells throughout the body, inorganic lead
exerts a wide spectrum of multisystemic
adverse effects. These health impacts range
from subtle, subclinical changes in function
to symptomatic, life-threatening intoxication.
In recent years, research conducted on lead-
exposed adults has increased public health
concern over the toxicity of lead at low dose.
These findings support a reappraisal of the
levels of lead exposure, sustained for either
short or extended periods of time, that may
be safely tolerated in the workplace. In this
article we offer health-based recommenda-
tions on the management of lead-exposed
adults aimed at primary and secondary pre-
vention of lead-associated health problems.
As noted in the introduction to this mini-
monograph (Schwartz and Hu 2007) the
authors of this article are an independent sub-
group of an expert panel (8 of 13 members)
originally convened by the Association of
Occupational and Environmental Clinics
(www.aoec.org) to address these management
issues. In deriving the recommendations in
this article, we took note of a body of litera-
ture that establishes the potential for adverse
health effects at blood lead concentrations or
exposure levels permissible under current
workplace regulations established in the
1970s by the U.S. Occupational Safety and
Health Administration (OSHA). These regu-
lations generally require removal from lead
exposure when whole-blood lead concentra-
tions exceed 50 or 60 µg/dL. These values are
considerably above blood lead concentrations
of the general population of the United
States, which had a geometric mean of
12.8 µg/dL in the late 1970s (National
Center for Health Statistics 1984), and a
recent value of 1.45 µg/dL [U.S. Centers for
Disease Control and Prevention (CDC)
2005]. 
In setting forth our perspective on the rec-
ommended medical management of adult lead
exposure, the narrative of this article focuses
on four categories of health effects—hyperten-
sion, decrement in renal function, cognitive
dysfunction, and adverse reproductive
outcome—that have been the subject of much
recent research. The discussion of these end
points highlights those studies, that by virtue
of their design and scope, were particularly
influential in establishing the authors’ con-
cerns regarding the potential for adverse
health effects at low to moderate levels of lead
exposure in adults. Collectively, these effects
support the preventive medical management
strategies that are recommended in the tables.
A review of the extensive literature on the
health effects of lead is beyond the scope of
this article, but the reader is referred to
reviews on the cardiovascular and cognitive
impacts of lead on adults that appear else-
where in this mini-monograph (Navas-Acien
et al. 2007; Shih et al. 2007), as well as a
review on recent lead literature prepared by
the U.S. Environmental Protection Agency
(EPA) for its Air Quality Criteria for Lead
(U.S. EPA 2006). 
Table 1 is a summary of the adverse
health risks associated with different blood
lead concentrations and presents correspond-
ing medical management recommendations
that range from discussion of risks and
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Research conducted in recent years has increased public health concern about the toxicity of lead
at low dose and has supported a reappraisal of the levels of lead exposure that may be safely toler-
ated in the workplace. In this article, which appears as part of a mini-monograph on adult lead
exposure, we summarize a body of published literature that establishes the potential for hyperten-
sion, effects on renal function, cognitive dysfunction, and adverse female reproductive outcome in
adults with whole-blood lead concentrations < 40 µg/dL. Based on this literature, and our collec-
tive experience in evaluating lead-exposed adults, we recommend that individuals be removed
from occupational lead exposure if a single blood lead concentration exceeds 30 µg/dL or if two
successive blood lead concentrations measured over a 4-week interval are ≥ 20 µg/dL. Removal of
individuals from lead exposure should be considered to avoid long-term risk to health if exposure
control measures over an extended period do not decrease blood lead concentrations to < 10 µg/dL
or if selected medical conditions exist that would increase the risk of continued exposure.
Recommended medical surveillance for all lead-exposed workers should include quarterly blood
lead measurements for individuals with blood lead concentrations between 10 and 19 µg/dL, and
semiannual blood lead measurements when sustained blood lead concentrations are < 10 µg/dL. It
is advisable for pregnant women to avoid occupational or avocational lead exposure that would
result in blood lead concentrations > 5 µg/dL. Chelation may have an adjunctive role in the med-
ical management of highly exposed adults with symptomatic lead intoxication but is not recom-
mended for asymptomatic individuals with low blood lead concentrations. Key words: adult lead
exposure, blood lead, chelation, medical management, medical surveillance, pregnancy. Environ
Health Perspect 115:463–471 (2007). doi:10.1289/ehp.9784 available via http://dx.doi.org/
[Online 22 December 2006]reduction of lead exposure at low levels to
removal from lead exposure accompanied by
probable chelation therapy at the highest lev-
els. The designation of risks as either “short-
term” or “long-term,” depending on whether
the risks are associated with exposure lasting
less than or more than 1 year, reﬂects a quali-
tative understanding of the duration of lead
exposure that may be required to elicit cer-
tain adverse health effects of lead. For some
of the long-term risks, such as hypertension,
research employing noninvasive K-shell X-ray
ﬂuorescence measurement of lead in bone, a
biomarker of long-term cumulative exposure,
suggests that several years of sustained eleva-
tions in blood lead may be necessary for a
significant risk to emerge. The use of 1 year
as a cut-point in the table is not intended to
represent a sharp division, in terms of cumu-
lative dose, between what might constitute a
short-term versus a long-term risk nor does it
imply that a signiﬁcant long-term risk begins
to exist as soon as 1 year is surpassed. Blood
lead, a measure of the amount of lead circu-
lating in the tissues, reflects both recent
exogenous exposure as well as endogenous
redistribution of lead stored in bone.
The categorization of risks in Table 1 by
discrete intervals of blood lead concentration
is a qualitative assessment. In clinical practice,
substantial interindividual variability in the
susceptibility to symptomatic adverse effects
of lead is commonly observed. Factors that
might influence the risk of lead toxicity in
adults include preexisting disease affecting
relevant target organs (e.g., hypertension,
renal disease, or neurologic dysfunction),
nutritional deficiencies that modify the
absorption or distribution of lead (e.g., low
dietary calcium or iron deﬁciency), advanced
age, and genetic susceptibility. Although
recent studies suggest that polymorphisms in
specific genes may modify the toxicokinetics
and renal effects of lead (Theppeang et al.
2004; Weaver et al. 2006; Wu et al. 2003),
research ﬁndings at present are insufﬁcient to
conclusively identify genotypes that confer
increased risk.
Kosnett et al.
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Table 1. Health-based management recommendations for lead-exposed adults.
Blood lead level Short-term risks Long-term risks
(µg/dL) (lead exposure < 1 year) (lead exposure ≥ 1 year) Management
< 5 None documented None documented None indicated
5–9 Possible spontaneous abortion Possible spontaneous abortion Discuss health risks 
Possible postnatal developmental delay Possible postnatal developmental delay Reduce lead exposure for women who are or may become pregnant
Possible hypertension and kidney dysfunction
10–19 Possible spontaneous abortion Possible spontaneous abortion As above for BLL 5–9 µg/dL, 
Possible postnatal developmental delay Reduced birth weight plus: 
Reduced birth weight Possible postnatal developmental delay Decrease lead exposure
Hypertension and kidney dysfunction Increase biological monitoring
Possible subclinical neurocognitive deﬁcits Consider removal from lead exposure to avoid long-term risks if exposure 
control over an extended period does not decrease BLL < 10 µg/dL, or 
if medical condition present that increases risk with continued exposurea
20–29 Possible spontaneous abortion Possible spontaneous abortion Remove from lead exposure if repeat BLL measured in 4 weeks 
Possible postnatal developmental delay Possible postnatal developmental delay remains ≥ 20 µg/dL
Reduced birth weight Reduced birth weight
Hypertension and kidney dysfunction
Possible subclinical neurocognitive deﬁcits
30–39 Spontaneous abortion Spontaneous abortion Remove from lead exposure
Possible postnatal developmental delay Reduced birth weight
Reduced birth weight Possible postnatal developmental delay
Hypertension and kidney dysfunction 
Possible neurocognitive deﬁcits
Possible nonspeciﬁc symptomsb
40–79 Spontaneous abortion Spontaneous abortion Remove from lead exposure
Reduced birth weight Reduced birth weight Refer for prompt medical evaluation
Possible postnatal developmental delay Possible postnatal developmental delay Consider chelation therapy for BLL > 50 µg/dL with signiﬁcant
Nonspeciﬁc symptomsb Nonspeciﬁc symptomsb symptoms or signs of lead toxicity
Neurocognitive deﬁcits  Hypertension
Sperm abnormalities Kidney dysfunction/nephropathy 
Subclinical peripheral neuropathy 
Neurocognitive deﬁcits 
Sperm abnormalities 
Anemia
Colic
Possible gout
≥ 80 Spontaneous abortion Spontaneous abortion Remove from lead exposure
Reduced birth weight Reduced birth weight Refer for immediate/urgent medical evaluation
Possible postnatal developmental delay Possible postnatal developmental delay Probable chelation therapy
Nonspeciﬁc symptomsb Nonspeciﬁc symptomsb
Neurocognitive deﬁcits  Hypertension
Encephalopathy Nephropathy 
Sperm abnormalities Peripheral neuropathy
Anemia Neurocognitive deﬁcits 
Colic Sperm abnormalities
Anemia 
Colic 
Gout
BLL, blood lead level.
aMedical conditions that may increase the risk of continued exposure include chronic renal dysfunction (serum creatinine > 1.5 mg/dL for men and > 1.3 mg/dL for women, or protein-
uria), hypertension, neurologic disorders, and cognitive dysfunction. bNonspeciﬁc symptoms may include headache, fatigue, sleep disturbance, anorexia, constipation, arthralgia, myal-
gia, and decreased libido.Health Effects at Low Dose
Hypertension. Animal investigations support
a pressor effect of lead at low dose (Fine et al.
1988; Gonick et al. 1997; Vaziri 2002).
Epidemiologic investigations conducted in
large general population samples (e.g., Harlan
1988; Nash et al. 2003; Pocock et al. 1988;
Schwartz 1988) suggest lead may elevate
blood pressure in adults at blood lead concen-
trations < 20 µg/dL. In some human studies
of the link between blood lead and blood
pressure, the relationship appeared to be
inﬂuenced by subjects’ sex or race (e.g., Den
Hond et al. 2002; Staessen et al. 1996;
Vupputuri et al. 2003). Three meta-analyses
of studies examining the relationship between
blood lead and blood pressure found rela-
tively consistent effects of blood lead on blood
pressure. The studies showed statistically signif-
icant coefﬁcients for a 2-fold increase in blood
lead of 1.0 mmHg (Nawrot et al. 2002;
Staessen et al. 1994) or 1.25 mmHg (Schwartz
1995) for systolic blood pressure, and
0.6 mmHg for diastolic blood pressure
(Nawrot et al. 2002; Staessen et al. 1994).
The study populations analyzed in these
meta-analyses included many with blood lead
concentrations < 20 µg/dL. 
Further support for the impact of low-
level lead exposure on blood pressure has
emerged from studies employing K-shell
X-ray fluorescence measurement of lead in
bone, a biomarker of long-term cumulative
lead exposure. In two major studies drawn
from samples of the general population, bone
lead concentration was a signiﬁcant predictor
of the risk of hypertension (Hu et al. 1996;
Korrick et al. 1999). Findings from the study
by Hu et al. (1996) illustrate the associated
risk. In that general population sample of
middle-aged to elderly men (n = 590), the
average blood lead concentration was
6.3 µg/dL. On the basis of the subjects’ ages
(mean 67 ± 7.2 years), it may be expected
that they lived most of their adult lives at a
time when the blood lead concentration of
the general population ranged from 10 to
25 µg/dL (Hofreuter et al. 1961; Mahaffey
et al. 1982; Minot 1938). Comparing the
lowest with the highest quintile of bone lead
among that cohort, a tibia bone lead incre-
ment of 29 µg/g was associated with a 1.5
odds ratio (OR) for hypertension [95% conﬁ-
dence interval (CI), 1.1–1.8]. Given the slope
of 0.05 that has described the linear relation-
ship between tibia bone lead concentration
and cumulative blood lead index in subjects
with chronic lead exposure in many studies
(Hu et al. 2007), this increment in bone lead
is roughly equivalent to a cumulative blood
lead index of 580 µg/dL • years (i.e., 29 ÷
0.05 = 580). Considered in the context of a
40-year working lifetime, the risk of lead-
associated hypertension may be significantly
reduced by preventive measures that lower
chronic workplace blood lead concentrations
from the 20s and 30s µg/dL range to
< 10 µg/dL. For example, a change in average
workplace blood lead concentration from
25 to 10 µg/dL over a 40-year working life-
time would reduce a worker’s cumulative
blood lead index by 600 µg/dL •years, slightly
more than the 580 µg/dL •years cited above. 
Hypertension is a significant risk factor
for cardiovascular and cerebrovascular mortal-
ity. As reviewed in an accompanying article in
this mini-monograph (Navas-Acien et al.
2007), studies conducted in general popula-
tion cohorts have consistently observed a pos-
itive association between lead exposure and
cardiovascular disease. Because of their size
and design, studies derived from the National
Health and Nutrition Evaluation Surveys
(NHANES) are particularly notable. A
16-year longitudinal analysis of the general
population cohort studied between 1976 and
1980 as part of NHANES II found that
blood lead concentrations of 20–29 µg/dL at
baseline were associated with 39% increased
mortality from circulatory system disease
compared with subjects with blood lead
< 10 µg/dL [relative risk (RR) 1.39; 95% CI,
1.01–1.91] (Lustberg and Silbergeld 2002).
Two studies recently examined the longi-
tudinal relationship between blood lead con-
centration and cardiovascular mortality
among participants in NHANES III. In a
12-year longitudinal study of participants in
NHANES III, ≥ 40 years of age (n = 9,757),
the subgroup with blood lead concentration
≥ 10 µg/dL (median, 11.8) had a relative risk
of cardiovascular mortality of 1.59 (95% CI,
1.28–1.98) compared with subjects with
blood lead < 5 µg/dL (Schober et al. 2006).
In a 12-year longitudinal analysis of subjects
≥ 17 years of age (n = 13,946), the relative
risk for cardiovascular mortality was 1.53
(95% CI, 1.21–1.94), comparing a blood
lead of 4.92 µg/dL (80th percentile of the dis-
tribution) with a blood lead of 1.46 µg/dL
(20th percentile of the distribution) (Menke
et al. 2006). 
Renal effects. Renal injury that appears
after acute high-dose lead exposure may
include reversible deﬁcits in proximal tubular
reabsorption and prerenal azotemia induced
by renal vasoconstriction and/or volume
depletion (Coyle et al. 200; Wedeen et al.
1979). In a minority of exposed individuals,
years of chronic, high-dose lead exposure may
result in chronic lead nephropathy, a slowly
progressive interstitial fibrosis characterized
by scant proteinuria (Lilis et al. 1968).
Epidemiologic investigations of renal function
in workers with lower levels of chronic lead
exposure have yielded variable findings. For
example, in a cohort of approximately 800
current and former lead workers with mean
blood lead of 32 ± 15 µg/dL, there was no
significant linear relationship between blood
lead concentration and two measures of renal
function, serum creatinine and creatinine
clearance (Weaver et al. 2003). There was an
interaction between age and tibia lead concen-
tration, a biomarker of cumulative lead expo-
sure, on these same biomarkers, resulting in a
trend toward worse renal function with
increasing bone lead in the oldest tercile of
workers (> 46 years of age) but improved renal
function with increasing bone lead in the
youngest workers (≤ 36 years of age). The
authors suggested that lead-induced hyperﬁl-
tration, a ﬁnding noted in other studies, might
presage the eventual development of lead-
induced renal insufficiency. Both blood lead
and tibia lead were correlated with increased
urinary N-acetyl-β-D-glucosaminidase (NAG),
a biomarker of early biological effect on the
renal tubule, but in an analysis of a smaller
subset of the lead workers (n = 190) that con-
trolled for the relatively low levels of urinary
cadmium (1.1 ± 0.78 µg/g creatinine), only
the relationship with tibia lead and NAG
remained significant (Weaver et al. 2003).
Among a cohort of 70 active lead workers
with a median blood lead concentration of
32 µg/dL (range, 5–47), there were modest
correlations between blood lead and urinary
β-2-microglobulin (r = 0.27; p = 0.02), and
between cumulative blood lead index and
NAG (r = 0.25; p = 0.04) (Gerhardsson et al.
1992).
Several studies conducted in general popu-
lation samples have reported an association
between blood lead concentration and com-
mon biomarkers of renal function (serum
creatinine and creatinine clearance). In a cross-
sectional investigation of a subcohort of mid-
dle-aged to elderly men enrolled in the
Normative Aging Study (n = 744), there was a
negative correlation between blood lead (mean,
8.1 ± 3.9 µg/dL; range, < 4.0–26.0 µg/dL) and
measured creatinine clearance, after natural
log transformation of both variables and
adjustment for other covariates (Payton et al.
1994). Among an adult population that
included subjects with environmental cad-
mium exposure [n = 965 men (geometric
mean blood lead, 11.4 µg/dL; range,
2.3–72.5 µg/dL); n = 1,016 women (geomet-
ric mean blood lead, 7.5 µg/dL; range,
1.7–60.3 µg/dL)], log-transformed blood lead
concentration was inversely correlated with
measured creatinine clearance (Staessen et al.
1992). In a population-based study of Swedish
women 50–59 years of age (n = 820), low lev-
els of blood lead (mean 2.2 µg/dL; 5th–95th
percentiles, 1.1–4.6 µg/dL) were inversely
correlated with creatinine clearance and
glomerular filtration rate, after adjusting for
age, body mass index, urinary or blood cad-
mium, hypertension, diabetes, and regular use
Recommendations for medical management of adult lead
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(NSAID) medication (Akesson et al. 2005). 
Individuals with other risk factors for
renal disease, notably hypertension and dia-
betes, may be more susceptible to an adverse
impact of low-level lead exposure on renal
function. Among adults participating in
NHANES III (n = 15,211), blood lead was a
risk factor for elevated serum creatinine
(deﬁned as ≥ 99th percentile of the analyte’s
race and sex specific distributions, generally
> 1.2–1.5 mg/dL) and “chronic kidney dis-
ease” (deﬁned as an estimated glomerular ﬁl-
tration rate < 60 mL/min) only among
subjects with hypertension (n = 4813)
(Muntner et al. 2003). Compared with
hypertensives in the lowest quartile of blood
lead (range, 0.7–2.4 µg/dL), hypertensive
subjects in the next highest quartile of blood
lead (range, 2.5–3.8 µg/dL) had a covariate
adjusted OR for elevated serum creatinine of
1.47 (95% CI, 1.03–2.10) and for chronic
kidney disease of 1.44 (95% CI, 1.00–2.09).
At the next highest quartile of blood lead
(range, 3.9–5.9 µg/dL), the covariate-adjusted
OR for elevated serum creatinine was 1.80
(95% CI, 1.34–2.42), and for chronic kidney
disease it was 1.85 (95% CI, 1.32–2.59). In a
subcohort of middle-aged to elderly men par-
ticipating in the Normative Aging Study (n =
427, blood lead 4.5 ± 2.5 µg/dL), multiple
regression analysis revealed that log-trans-
formed blood lead was positively correlated
with serum creatinine in hypertensive but not
normotensive subjects (Tsaih et al. 2004). In
a longitudinal study of this cohort over a
mean of 6 years, an interaction between lead
and diabetes yielded a positive association
between baseline blood lead concentration
and change in serum creatinine that was
strongest in diabetic subjects (Tsaih et al.
2004). An interaction with diabetes was also
present in the association of tibial lead con-
centration with longitudinal change in serum
creatinine (Tsaih et al. 2004). Although these
general population studies are consistent with
an adverse effect of lead exposure on renal
function at notably low levels, the extent to
which diminished renal function may itself
result in increased body lead burden has not
been fully elucidated. 
Cognitive dysfunction. A few studies
examining relatively small numbers of work-
ers (n ≤ 100) with blood lead concentrations
ranging approximately 20–40 µg/dL have
associated lead exposure with subclinical
decrements in selective domains of neurocog-
nitive function (Barth et al. 2002; Hänninen
et al. 1998; Mantere et al. 1984; Stollery
1996). Among a large cohort of current and
former inorganic lead workers studied in
Korea, a cross-sectional analysis (n = 803
workers) (Schwartz et al. 2001) and a 3-year
longitudinal analysis (n = 576 workers)
(Schwartz et al. 2005) found that blood lead
concentrations across the approximate range
of 20–50 µg/dL were associated with subclini-
cal neurocognitive deficits. Among a small
population of former lead workers (n = 48)
and age-matched controls with similar blood
lead concentrations (approximately 5 µg/dL
in both groups; range, 1.6–14.5 µg/dL; mean
age, 39.8 years), increases in current blood
lead concentration within the entire study
population were correlated with poorer per-
formance on several tests of neurocognitive
function but on only one measure was cumu-
lative lead exposure (measured in the workers)
associated with poorer performance (Winker
et al. 2005). 
In the population-based sample of adults
20–59 years of age participating in the
NHANES III study (n = 4937), there was no
relationship between blood lead concentra-
tion (geometric mean, 2.51 µg/dL) and
covariate-adjusted performance on neu-
rocogntive function (Krieg et al. 2005).
However, significant associations have
emerged in some studies of older adults with
slightly higher blood lead concentrations. In a
rural subset of elderly women (mean age,
71.1 ± 4.7 years; n = 325) with background,
community lead exposure (geometric mean
blood lead concentration, 4.8 µg/dL; range,
1–21 µg/dL), certain measures of neuro-
psychologic function (Trailmaking part B and
Digit Symbol test) were performed more
poorly by women in the upper 15th per-
centile of blood lead (blood lead ≥ 8 µg/dL,
n = 38; Muldoon et al. 1996). However, in
the slightly younger subset of elderly women
who resided in an urban area (mean age,
69.4 ± 3.8 years; n = 205), no relationship
between blood lead (geometric mean,
5.4 µg/dL) and neuropsychologic perfor-
mance was discernible (Muldoon et al. 1996).
In a general population sample of middle-
aged to elderly men (n = 141; mean age,
66.8 ± 6.8 years) with a mean blood lead con-
centration of 5.5 ± 3.5 µg/dL examined as
part of the Normative Aging Study, increased
blood lead concentration was associated with
poorer performance on neuropsychologic
assessment of memory, verbal ability, and
mental processing speed (Payton et al. 1998).
In a larger subset of men (n = 736; mean age,
68.2 ± 6.9 years) from the Normative Aging
Study assessed with the Mini-Mental Status
Examination (MMSE), the OR for having a
test score associated with an increased risk of
dementia was 3.4 (95% CI, 1.6–7.2) compar-
ing the mean blood lead of the highest quar-
tile (mean, 8.9 µg/dL) to that of the lowest
quartile (mean, 2.5 µg/dL) (Wright et al.
2003). There was a positive interaction
between age and blood lead, which is consis-
tent with a lead-associated acceleration in age-
related neurodegeneration. 
As reviewed in an accompanying article in
this mini-monograph (Shih et al. 2007), there
is evidence that at low levels of lead exposure,
biomarkers of cumulative lead exposure, such
as lead in bone, may be associated with an
adverse impact on neurocognitive function
that is not reflected by measurement of
lead in blood. Among subjects from the
Normative Aging Study (n = 466; mean age,
67.4 ± 6.6 years) examined for longitudinal
change in MMSE score over an average of
3.5 ± 1.1 years, higher patella bone lead con-
centrations, a biomarker of cumulative lead
exposure, predicted a steeper decline in per-
formance (Weisskopf et al. 2004). By com-
parison, baseline blood lead concentration
(median, 4 µg/dL; interquartile range = 3, 5)
did not predict change in MMSE score. In a
longitudinal analysis of performance on a bat-
tery of cognitive tests in a subset of the
Normative Aging Study, bone lead measure-
ments were predictive of worsening perfor-
mance over time on tests of visuospatilal/
visuomotor ability (Weisskopf et al. 2007). In
a cross-sectional analysis of 985 community
dwelling residents 50–70 years of age, increas-
ing tibia bone lead concentrations were sig-
nificantly associated with decrements in
cognitive function, whereas an impact of
blood lead (mean, 3.46 ± 2.23 µg/dL) was
not apparent (Shih et al. 2006). 
Reproductive outcome in women. Adverse
effects on reproductive outcome constitute a
special risk of lead exposure to women of
reproductive age. A nested case–control study
examined the association of blood lead con-
centration with spontaneous abortion in a
cohort of 668 pregnant women seeking pre-
natal care in Mexico City (Borja-Aburto et al.
1999). After matching for maternal age, edu-
cation, gestational age at study entry, and
other covariates, the OR for spontaneous
abortion before 21 weeks gestation was 1.13
(95% CI, 1.01–1.30) for every 1 µg/dL
increase in blood lead across the blood lead
range of 1.4–29 µg/dL. Compared with the
reference category of < 5 µg/dL of blood lead,
women whose blood lead levels were 5–9,
10–14, and > 15 µg/dL had ORs for sponta-
neous abortion of 2.3, 5.4, and 12.2, respec-
tively (test for trend, p = 0.03). Although
several earlier studies failed to detect this sub-
stantial impact, they may have been subject
to methodologic limitations not present in
the Mexico City investigation (Hertz-
Picciotto 2000). 
Several studies have found that lead expo-
sure during pregnancy affects child physical
development measured during the neonatal
period and early childhood. In an extensively
studied cohort of 272 full-term, parturient
women from Mexico City with environmental
lead exposure common to the region (mean
maternal blood lead, 8.9 ± 4.1 µg/dL; mean
Kosnett et al.
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12–38 µg/g), every increase of 10 µg/g in
maternal tibia lead was associated with a 73-g
(95% CI, 25–121) decrease in birth weight
(Gonzalez-Cossio et al. 1997). The impact of
tibia bone lead on birth weight was nonlinear
and was most pronounced in mothers with the
highest quartile of bone lead (> 15–38 µg/g)
where the decrement relative to the lowest
quartile was estimated to be 156 g. Primarily
in the same cohort, a maternal patella lead
concentration > 24.7 µg/g was associated with
an OR of 2.35 (95% CI, 1.26–4.40) for a
neonate with one category smaller head cir-
cumference at birth, assessed as a five-cate-
gory–ordered variable (Hernandez-Avila et al.
2002). In a different Mexico City cohort, each
doubling of maternal blood lead at 36 weeks
of pregnancy (geometric mean, 8.1 µg/dL;
25th–75th percentile, 5–12 µg/dL) was associ-
ated with a decrease of 0.37 cm (95% CI,
0.57–0.17) in the head circumference of a
6-month-old infant (Rothenberg et al.
1999b). 
Prenatal lead exposure assessed by umbili-
cal cord blood lead concentration has been
inconsistently associated with an adverse effect
on neurobehavioral development in childhood.
However, recent studies suggest that mobiliza-
tion of maternal bone lead during pregnancy
may contribute to fetal lead exposure in ways
that may be incompletely reﬂected by the sin-
gle measurement of umbilical cord whole-
blood lead (Chuang et al. 2001; Tellez-Rojo
et al. 2004). In a prospective study conducted
in Mexico City of 197 mother–infant pairs, a
statistically signiﬁcant adverse effect of umbili-
cal cord blood lead (mean, 6.7 ± 3.4 µg/dL;
range, 1.2–21.6 µg/dL) was also accompanied
by an independent adverse effect of maternal
bone lead burden on the 24-month Mental
Development Index (MDI) of the Bayley
Scales of Infant Development, which
decreased 1.6 points (95% CI, 0.2–3.0) for
every 10-µg/g increase in maternal patellar
lead (mean, 17.9 ± 15.2 µg/g; range,
< 1–76.6 µg/g) (Gomaa et al. 2002). 
A prospective study that measured mater-
nal plasma lead and maternal whole-blood
lead during pregnancy found that maternal
plasma lead during the ﬁrst trimester was the
stronger predictor of infant mental develop-
ment at 24 months of age (Hu et al. 2006).
In this cohort, ﬁrst trimester maternal plasma
lead was 0.016 ± 0.014 µg/dL and first
trimester maternal whole-blood lead was
7.07 ± 5.10 µg/dL (n = 119). Adjusting for
covariates that included maternal age, mater-
nal IQ, child sex, childhood weight and
height for age, and childhood whole-blood
lead at 24 months, an increase of one SD in
loge (natural log)–transformed plasma lead in
the first trimester was associated with a
3.5-point decrease in score on the 24-month
MDI of the Bayley Scales of Infant
Development. The corresponding impact of
one SD increase in loge maternal whole
blood during the first trimester was a
2.4-point decrease in the 24-month MDI.
The logarithmic relationship between mater-
nal plasma and blood lead concentrations
and infant MDI indicated that the strongest
effects occurred among mothers with the
lowest plasma and blood lead concentrations.
Two long-term prospective studies that
conducted multiple measurements of mater-
nal blood lead during pregnancy and child-
hood have identified an adverse impact of
low-level prenatal lead exposure on postnatal
neurobehavioral development extending
beyond infancy. Applying a repeated mea-
sures linear regression technique to analysis of
age-appropriate IQ test data obtained in 390
children 3–7 years of age, the Yugoslavia
Prospective Lead Study found independent
adverse effects of both prenatal and postnatal
blood lead. After controlling for the pattern
of change in postnatal blood lead and other
covariates, IQ decreased 1.8 points (95% CI,
1.0–2.6) for every doubling of prenatal blood
lead, which was assessed as the average of
maternal blood lead at midpregnancy and
delivery (mean, 10.2 ± 14.4 µg/dL; n = 390)
(Wasserman et al. 2000). The Mexico City
Prospective Lead Study used generalized lin-
ear mixed models with random intercept and
slope to assess the impact on IQ measured at
6–10 years of age of blood lead measurements
systematically obtained during weeks 12, 20,
24, and 36 of pregnancy, at delivery, and at
multiple points throughout childhood
(Schnaas et al. 2006). Geometric mean blood
lead during pregnancy was 8.0 µg/dL (range,
1–33 µg/dL; n = 150); from 1 through 5 years
it was 9.8 µg/dL (2.8–36.4 µg/dL), and from
6 through 10 years it was 6.2 µg/dL (range,
2.2–18.6 µg/dL). IQ at 6 to 10 years of age,
assessed by the Wechsler Intelligence Scale for
Children—Revised, decreased significantly
only with increasing natural-log third-
trimester blood lead, controlling for other
blood lead measurements and covariates.
Every doubling of third trimester blood lead
(geometric mean of maternal blood lead at
weeks 28 and 36 = 7.8 µg/dL, 5th–95th per-
centile: range, 2.5–24.6 µg/dL) was associated
with an IQ decrement of 2.7 points (95% CI,
0.9–4.4). Notably, the nonlinear (i.e., log-lin-
ear) relationships detected in the Yugoslavia
and Mexico City studies indicate that across a
maternal blood lead range of 1–30 µg/dL, an
increase in blood lead from 1 to 10 µg/dL will
account for more than half the IQ decrement. 
Two independent cohorts have provided
evidence that maternal lead burden during
pregnancy may be associated with increased
risk of pregnancy hypertension and/or ele-
vated blood pressure during pregnancy. In a
retrospective study of 3,210 women during
labor and delivery, increasing umbilical cord
blood lead levels (mean, 6.9 ± 3.3 µg/dL;
range, 0–35 µg/dL) were associated with
increased systolic blood pressure during labor
(1.0 mmHg for every doubling of blood lead)
and increased odds of hypertension (not fur-
ther deﬁned) recorded any time during preg-
nancy (OR = 1.3; 95% CI, 1.1–1.5) for every
doubling of blood lead (Rabinowitz et al.
1987). A prospective study of third trimester
blood lead (geometric mean, 2.3 ± 1.4 µg/dL;
range, 0.5–36.5 µg/dL) in 1,188 predomi-
nantly Latina immigrants showed that, in the
immigrants, every doubling in blood lead was
associated with increased third-trimester sys-
tolic blood pressure (1.2 mmHg; 95% CI,
0.5–1.9) and diastolic blood pressure
(1.0 mmHg; 95% CI, 0.4–1.5) (Rothenberg
et al. 1999a). A study of a subset of the same
cohort (n = 637) without regard to immigra-
tion status found that every 10-µg/g increase
in calcaneus (heel) bone lead increased the
OR of third trimester pregnancy hypertension
(systolic > 90 and/or diastolic > 140 mmHg)
by 1.86 (95% CI, 1.04–3.32) (Rothenberg
et al. 2002).
Medical Surveillance for
Lead-Exposed Workers
The OSHA workplace standard for lead
exposure in general industry (adopted in
1978) and a corresponding standard for lead
exposure in construction trades (adopted in
1993) set forth medical surveillance require-
ments that include baseline and periodic
medical examinations and laboratory testing.
Details of the two standards, which establish
distinct criteria for the implementation of
surveillance, can be found on the OSHA
website (OSHA 2002). Because of the con-
cern regarding adverse health effects of lead
associated with the lower levels of exposure
discussed in this article, we recommend a
revised schedule of medical surveillance activ-
ities (Table 2). Unlike the OSHA medical
surveillance requirements, which apply only
to workers exposed to airborne lead levels
≥ 30 µg/m3 as an 8-hr time-weighted aver-
age, the recommendations in Table 2 are
intended to apply to all lead-exposed workers
who have the potential to be exposed by lead
ingestion, even in the absence of documented
elevations in air lead levels (Sen et al. 2002).
As shown in Table 2, the level of a worker’s
current blood lead measurement, as well as
possible changes in lead-related exposure,
inﬂuences the recommended time interval for
subsequent blood lead measurements. Blood
lead measurements should be obtained from
a clinical laboratory that has been designated
by OSHA as meeting the speciﬁc proﬁciency
requirements of the OSHA lead standards.
OSHA maintains a list of these laboratories
Recommendations for medical management of adult lead
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should be used for biological monitoring of
adult lead exposures, except where prohibited
by medical or other reasons. Routine meas-
urement of zinc protoporphyrin, a require-
ment of the OSHA lead standards, is not
recommended in Table 2 because it is an
insensitive biomarker of lead exposures in
individuals with blood lead concentrations
< 25 µg/dL (Parsons et al. 1991). 
The content of the baseline or preplace-
ment history and physical examination for
lead-exposed workers should continue to fol-
low the comprehensive scope set forth in the
OSHA lead standard for general industry.
Measurement of serum creatinine will iden-
tify individuals with chronic renal dysfunc-
tion who may be subject to increased health
risks from lead exposure. With the potential
exception of an annual blood pressure meas-
urement and a brief questionnaire regarding
the presence of medical conditions (such as
renal insufficiency) that might increase the
risk of adverse health effects of lead exposure,
medical evaluations for lead-exposed workers
should be unnecessary as long as blood lead
concentrations are maintained < 20 µg/dL.
Annual education of lead workers regarding
the nature and control of lead hazards, and
ongoing access to health counseling regarding
lead-related health risks are recommended as
preventive measures.
Lead Exposure during
Pregnancy and Lactation
As summarized earlier in this article, the recent
ﬁndings concerning lead-related adverse repro-
ductive outcomes render it advisable for preg-
nant women to avoid occupational or
avocational lead exposure that would result in
blood lead concentrations > 5 µg/dL. Calcium
supplementation during pregnancy may be
especially important for women with past
exposure to lead. Calcium decreases bone
resorption during pregnancy (Janakiraman
et al. 2003) and may minimize release of lead
from bone stores and subsequent fetal lead
exposure (Gomaa et al. 2002). 
Maternal body lead burden and external
lead exposure influence the lead concentra-
tion of breast milk (Ettinger et al. 2006;
Gulson et al. 1998). The few studies that
used ultraclean techniques and mass spec-
trometry analyses report human breast milk
concentrations ranging from 0.6 to 3% of
maternal blood lead (Ettinger et al. 2004b;
Gulson et al. 1998; Manton et al. 2000;
Sowers et al. 2002). Using 1% as a guide, it
can be estimated that nursing mothers with a
blood lead concentration < 20 µg/dL will
have breast milk with a concentration
< 2 µg/L, a value that approximates the
amount of lead in infant formula (Gulson
et al. 2001). A recent randomized clinical
trial among Mexican women with mean
blood lead concentrations of approximately
9 µg/dL found that calcium supplementation
during lactation may reduce the lead concen-
tration of breast milk by 5–10% (Ettinger
et al. 2006). Breast feeding should be encour-
aged for almost all women (Ettinger et al.
2004a; Sanin et al. 2001; Sinks and Jackson
1999), with decisions concerning women
with very high lead exposure addressed on an
individual basis. 
Medical Treatment of Elevated
Blood Lead Concentration and
Overt Lead Intoxication
Removal from all sources of hazardous lead
exposure, whether occupational or nonoccu-
pational, constitutes the ﬁrst and most funda-
mental step in the treatment of an individual
with an elevated blood lead concentration. A
careful history that inquires about a broad
spectrum of potential lead sources is recom-
mended (Occupational Lead Poisoning
Prevention Program 2006). Removal from
occupational lead exposure will usually require
transfer of the individual out of any environ-
ment or task that might be expected to raise
the blood lead concentration of a person not
using personal protective equipment above
background levels (i.e., 5 µg/dL). If there has
been a history of an affected individual bring-
ing lead-contaminated shoes, work clothes, or
equipment home from the workplace, evalua-
tion of vehicles and the home environment for
signiﬁcant levels of lead-containing dust might
be considered (Piacitelli et al. 1995). Although
such “take-home” exposure might contribute
to further lead exposure of the worker, it ordi-
narily poses more of a potential risk to young
children and pregnant or nursing women who
share the worker’s home environment
(Hipkins et al. 2004; Roscoe et al. 1999).
Medical treatment of individuals with
overt lead intoxication involves decontamina-
tion, supportive care, and judicious use of
chelating agents. Comprehensive discussion
of such treatment is beyond the scope of this
article but has been reviewed in recent med-
ical toxicology texts (Kosnett 2001, 2005). A
variety of chelating agents has been demon-
strated to decrease blood lead concentrations
and increase urinary lead excretion. A recent
double-blind randomized clinical trial of oral
chelation in young children with blood lead
concentrations ranging from 22 to 44 µg/dL
found that the drug succimer lowered blood
concentrations transiently but did not
improve cognitive function (Dietrich et al.
2004; Rogan et al. 2001). Although anecdotal
evidence suggests that chelation has been
associated with improvement in symptoms
and decreased mortality in patients with lead
encephalopathy, controlled clinical trials
demonstrating efﬁcacy are lacking. Treatment
recommendations are therefore mostly
empiric, and decisions regarding the initiation
of chelation therapy for lead intoxication have
occasionally engendered controversy.
In our experience, adults with blood lead
concentrations ≥ 100 µg/dL almost always
warrant chelation, as levels of this magnitude
are often associated with signiﬁcant symptoms
and may be associated with an incipient risk of
encephalopathy or seizures. Occasionally,
patients with very high blood lead con-
centrations may have no overt symptoms.
Patients with blood lead concentrations of
80–99 µg/dL, with or without symptoms, can
be considered for chelation treatment, as may
some symptomatic individuals with blood
lead concentrations of 50–79 µg/dL. These
demarcations are imprecise, however, and
decisions on chelation should be made on a
case-by-case basis after consultation with an
Kosnett et al.
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Table 2. Health-based medical surveillance recommendations for lead-exposed workers.
Category of exposure Recommendations
All lead-exposed workersa Baseline or preplacement medical history and physical examination, baseline 
BLL, serum creatinine
BLL (µg/dL)
< 10 BLL every month for ﬁrst 3 months of placement, or upon change in task to 
higher exposure, then BLL every 6 months
If BLL increases ≥ 5 µg/dL, evaluate exposure and protective measures. 
Increase monitoring if indicated
See Table 1 for pregnancy concerns
10–19 As above for BLL < 10 µg/dL, plus:
BLL every 3 months
Evaluate exposure, engineering controls, and work practices
Consider removal (see Table 1)
Revert to BLL every 6 months after 3 BLLs < 10 µg/dL
≥ 20 Remove from exposure if repeat BLL measured in 4 weeks remains ≥ 20 µg/dL, 
or if ﬁrst BLL ≥ 30 µg/dL (see Table 1)
Monthly BLL testing
Consider return to lead work after 2 BLLs < 15 µg/dL a month apart, then 
monitor as above
BLL, blood lead level.
aLead-exposed means handling or disturbing materials with a signiﬁcant lead content in a manner that could reasonably
be expected to cause potentially harmful exposure through inhalation or ingestion.experienced specialist in occupational medi-
cine or medical toxicology.
Hair lead analysis or measurement of
urine lead concentration seldom provide
exposure information of clinical value beyond
that provided by the history and the measure-
ment of blood lead concentration. Chelation
initiated exclusively on the basis of hair or
urine lead levels or chelation of asymptomatic
individuals with low blood lead concentra-
tions is not recommended.
Adults with overt lead intoxication will
generally experience improvement in symp-
toms after removal from lead exposure and
decline in blood lead concentration. This clini-
cal observation on improvement in overt
symptoms ﬁnds some support from the rela-
tively limited number of studies that have
examined the impact of naturally declining
blood lead concentrations on cognitive func-
tion in occupationally exposed subjects
(Chuang et al. 2005; Lindgren et al. 2003;
Winker et al. 2006). Improvement or resolu-
tion of neurocognitive or neurobehavioral
symptoms may sometimes lag the decline in
blood lead concentration, possibly because of
the relatively slower removal of lead from the
central nervous system (Cremin et al. 1999;
Goldstein et al. 1974). The pace of improve-
ment can be highly variable, and may range
from weeks to a year or more depending on
the magnitude of intoxication. Anecdotal expe-
rience and analogy to other forms of brain
injury suggest a potential role for rehabilitative
services (e.g., physical therapy, cognitive reha-
bilitation) in enhancing the prospect for recov-
ery, and in demonstrating the capacity for safe
return to work. Short-term improvement in
neurocognitive function associated with a
decline in blood lead concentration does not
obviate concern that long-term cumulative lead
exposure may nonetheless have a deleterious
effect on cognitive reserve, and may accelerate
age-related decline in cognitive function
(Schwartz et al. 2005; Weisskopf et al. 2004). 
Additional Management
Considerations
With appropriate engineering controls, safe
work practices, and personal protective equip-
ment, workers without a previous history of
substantial lead exposure should be able to
work with lead in a manner that minimizes
the potential for hazardous levels of exposure.
For such workers, elevations in blood lead
concentration that result from unforeseen
transient increases in exposure will often
decline promptly once the exposure is con-
trolled. However, in a worker with a long his-
tory of high exposure, redistribution of lead
from a large internal skeletal burden may
result in a prolonged elevation of blood lead
concentration despite marked reductions in
external lead dose.
The recommendations for management of
adult lead exposure contained in this article are
derived from consideration of risks to health,
and have not been the subject of a cost-beneﬁt
analysis examining economic feasibility or
social impacts. Nonmedical, socioeconomic
factors will likely influence how workers,
employers, and clinicians respond to the rec-
ommendations. In particular, the blood lead
concentrations for which some major interven-
tions, such as removal from lead exposure, are
recommended are considerably lower than
those explicitly speciﬁed in the current OSHA
lead standards (OSHA 2002). The OSHA
standards do require an employer to imple-
ment reductions in exposure recommended by
a physician who determines an employee has a
“detected medical condition” that places him
or her at increased risk of “material impair-
ment to health.” This nonspecific provision
could form the basis for implementation of
protective workplace action at the lower blood
concentrations recommended by the authors.
Nonetheless, clinicians should inform patients
that such recommendations may be contested
by an employer or an insurer, and could poten-
tially jeopardize their job benefits or work
status. Prudent case management that consid-
ers the worker’s perspective on their unique
health risks and employment situation will
usually be advisable.
Interpretative Guidance for
Clinical Laboratory Report
Forms
Clinical laboratories routinely offer brief
interpretative guidance on the forms that
report the result of blood lead concentrations.
There is considerable variability among labo-
ratories regarding the content of such guid-
ance, and laboratories exercise their own
discretion regarding the source and detail of
the information they provide. Unlike the
management guidance chart for childhood
blood lead concentrations published by the
CDC (2002), which is often reproduced by
clinical laboratories, no corresponding CDC
guidance exists for blood lead concentrations
measured in adults. Notwithstanding the lim-
itations inherent in an abbreviated tabular
format, Table 3 represents a guidance chart
for adult blood lead measurements that is
proposed for use by clinical laboratories.
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